Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists

Thrombosis and Haemostasis

Volumn 117, Issue 4, 2017, Pages 784-793

  Di Nisio, Marcello ^a,b   Raskob, Gary ^c   Büller, Harry R ^b   Grosso, Michael A ^d   Zhang, George ^d   Winters, Shannon M ^d   Cohen, Alexander ^e  

^a UNIVERSITY OF CHIETI   (Italy)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^d DAIICHI SANKYO INC   (United States)

^e GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Anticoagulants; Haemorrhage; Risk factors; Thrombosis; Venous thromboembolism

Indexed keywords

EDOXABAN; HEMOGLOBIN; HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; QUINIDINE; VERAPAMIL; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE; VITAMIN K GROUP;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BLEEDING RISK SCORE; BLOOD TRANSFUSION; CLINICAL OUTCOME; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE CLEARANCE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EDOXABAN SCORE; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HAS BLED SCORE; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; KEARON SCORE; KUIJER SCORE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MEDICAL HISTORY; MULTICENTER STUDY; ORBIT SCORE; OUTPATIENT BLEEDING RISK INDEX; PHASE 2 CLINICAL TRIAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; RACE; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RIVAROXABAN SCORE; SYSTOLIC BLOOD PRESSURE; THROMBOCYTOPENIA; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD CLOTTING; CHEMICALLY INDUCED; CLINICAL TRIAL; DECISION SUPPORT SYSTEM; DRUG EFFECTS; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; PREDICTIVE VALUE; RISK FACTOR; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; BLOOD COAGULATION; DECISION SUPPORT TECHNIQUES; DOUBLE-BLIND METHOD; FACTOR XA INHIBITORS; FEMALE; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PYRIDINES; RISK ASSESSMENT; RISK FACTORS; THIAZOLES; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VITAMIN K; WARFARIN;

EID: 85013666270     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH16-11-0830     Document Type: Article

References (27)

1. Hokusai-VTE Investigators, Büller HR, Décousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369: 1406-1415.
2. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 2016; 149: 315-352.
3. van Es N, Coppens M, Schulman S, et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014; 124: 1968-1975.
4. Carrier M, Le Gal G, Wells PS, Rodger MA. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med 2010; 152: 578-589.
5. Ruíz-Giménez N, Suárez C, González R, et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008; 100: 26-31.
6. Nieto JA, Solano R, Ruiz-Ribó MD, et al. Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: _ndings from the RIETE registry. J Thromb Haemost 2010; 8: 1216-1222.
7. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989; 87: 144-152.
8. Landefeld CS, Cook EF, Flatley M, et al. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 1987; 82: 703-713.
9. Beyth BJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105: 91-99.
10. Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood 1991; 78: 2337-2343.
11. Kuijer PMM, Hutten BA, Prins MH, Büller HR. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999; 159: 457-460.
12. Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349: 631-639.
13. Wells PS, Forgie MA, Simms M, et al. The outpatient bleeding risk index validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism. Arch Intern Med 2003; 163: 917-920.
14. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-1100.
15. Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage. The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011; 58: 395-401.
16. O’Brien EC, Simon DN, Thomas LE, et al The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial _brillation. Eur Heart J 2015; 36: 3258-3264.
17. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151: 713-719.
18. Rodger M, Carrier M, Gandara E, Le Gal G. Unprovoked venous thromboembolism: Short term or indefinite anticoagulation? Balancing long-term risk and benefit. Blood Rev 2010; 24: 171-178.
19. Kearon C, Iorio A, Palareti G, Subcommittee on Control of Anticoagulation of the SSC of the ISTH. Risk of recurrent venous thromboembolism after stopping treatment in cohort studies: recommendation for acceptable rates and standardized reporting. J Thromb Haemost 2010; 8: 2313-2315.
20. Hosmer Jr DW, Lemeshow S, Sturdivant RX. In: Applied Logistic Regression. 3rd ed. Wiley Series in Probability & Statistics; 2013.
21. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-387.
22. Di Nisio M, Ageno W, Rutjes AW, et al. Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists. Thromb Haemost 2016; 115: 424-432.
23. Poli D, Antonucci E, Testa S, et al. Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation. Circulation 2011; 124: 824-829.
24. Donzé J, Rodondi N, Waeber G, et al. Scores to predict major bleeding risk during oral anticoagulation therapy: a prospective validation study. Am J Med 2012; 125: 1095-1102.
25. Riva N, Bellesini M, Di Minno MN, et al. Poor predictive value of contemporary bleeding risk scores during long-term treatment of venous thromboembolism: A multicentre retrospective cohort study. Thromb Haemost 2014; 112: 511-521.
26. Burgess S, Crown N, Louzada ML, et al. Clinical performance of bleeding risk scores for predicting major and clinically relevant non-major bleeding events in patients receiving warfarin. J Thromb Haemost 2013; 11: 1647-1654.
27. Scherz N, Méan M, Limacher A, et al. Prospective, multicenter validation of prediction scores for major bleeding in elderly patients with venous thromboembolism. J Thromb Haemost 2013; 11: 435-443